News | May 09, 2007

Cedara, Varian Pen Licensing Agreement

May 10, 2007 - Cedara Software, a Merge Healthcare company, announced it has concluded a licensing agreement with Varian Medical Systems, giving Varian exclusive global rights to distribute Cedara’s I-Response technology within the radiation and medical oncology market.
Cedara I-Response is a tool that analyzes how cancerous tumors are responding to treatment. I-Response supports multiple imaging modalities and features patented analysis of fDM (Functional Diffusion Mapping) MR images. It allows professionals to visualize and quantify changes in tumor tissue resulting from cellular and metabolic mechanisms, and then track the data over time. In this way, Cedara I-Response has the potential to precisely monitor the impact of anti-cancer drugs and radiation therapy early in the course of treatment, adding to the information that clinicians can reference when developing personalized treatment plans.
Cedara I-Response complements Varian’s Dynamic Adaptive Radiation Therapy (DART) program with its image analysis capabilities that assist oncologists in making treatment decisions for their patients. Cedara I-Response has received FDA 510k clearance and the company expects a commercial release in June 2007.

Related Content

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

Pseudocolor accentuated CT scan image of a liver tumor. Image courtesy of Lucence Diagnostics.

News | Oncology Diagnostics | March 12, 2019
Genomic medicine company Lucence Diagnostics announced a new project to develop artificial intelligence (AI) algorithms...
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
February 13, 2019 — At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and e
New Appropriate Use Criteria Outlined for Multimodality Imaging of Nonvalvular Heart Disease
News | Cardiac Imaging | February 11, 2019
The American College of Cardiology (ACC), along with nine other cardiology professional societies, recently published a...
IMS to Unveil Prototype Imaging Machine Learning Platform at HIMSS19
News | Artificial Intelligence | February 06, 2019
International Medical Solutions (IMS) announced a solution that will enable radiologists and other clinicians to use...
Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support
News | Clinical Decision Support | February 05, 2019
Siemens Healthineers showcased the new planned artificial intelligence (AI)-based features with its mammography reading...
Infinitt Showcases New RIS/PACS Features at RSNA 2018
News | PACS | December 19, 2018
Infinitt North America highlighted a range of healthcare information technology (IT) products and applications at the...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...